Sangamo Therapeutics and Genentech Forge $1.9B License Agreement for Novel Neurodegenerative Disease Treatments

Richmond, CA, August 06, 2024 (Business Wire) -- Sangamo Therapeutics and Genentech have entered into a global license agreement to develop genomic medicines targeting neurodegenerative diseases, leveraging Sangamo's advanced epigenetic and delivery technologies. The agreement includes $50 million in upfront payments and milestones, with potential earnings of up to $1.9 billion in future milestones and royalties. This partnership highlights the potential of innovative gene therapies in addressing critical challenges in neurodegenerative disease treatment.

Read full article here.